Medicines Discovery Catapult

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Retrieved on: 
Wednesday, March 20, 2024
Medicines Discovery Catapult, Francis Crick Institute, AstraZeneca, Science, Drug discovery, Novartis, Fraunhofer, Patient, IPA, University, GE HealthCare, Biophysics, Fundamental, Investment, Pharmaceutical industry

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Key Points: 
  • Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
  • Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.
  • Keno Gutierrez, Chairman of the Board of FundaMental Pharma, commented: “We are excited to share that Lorenz, a seasoned and highly regarded industry leader, has joined our Board of Directors.
  • I am confident that Lorenz`s energy, conceptual guidance and reach will make a difference in advancing FundaMental Pharma`s key program to the next level.”

Exscientia Announces Expansion of its Technology Leadership Team

Retrieved on: 
Thursday, June 29, 2023
Health, Pharmaceutical, Technology, Health Technology, Artificial Intelligence, University College London, Medicines Discovery Catapult, Society, SAGE, University, Doctor of Philosophy, ChEMBL, Engineering, Head, Wellcome Trust, COVID-19, Chartered Institute of Architectural Technologists, Engineering and Physical Sciences Research Council, European Bioinformatics Institute, Woman, Medicine, UK Research and Innovation, Female, Drug design, Structural bioinformatics, Committee, Computer Weekly, Publication, Patient, Machine learning, Clinical Medicine & Research, UKRI, EBI, Physics, Drug discovery, Emergency, Artificial intelligence, STEM, AI, Research, Outline of physical science, Pfizer, Pharmaceutical industry, Management, Biochemistry, Chemistry

In addition, use of the company’s technology has grown far beyond medicinal chemistry, including personalised medicine, target identification and laboratory automation.

Key Points: 
  • In addition, use of the company’s technology has grown far beyond medicinal chemistry, including personalised medicine, target identification and laboratory automation.
  • The company’s change in management structure announced today will further align executive decision making with its functional priorities in technology.
  • “Under Garry's leadership, Exscientia has built a scalable technology stack, established automation laboratories and grown its technology team to over 200 employees,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.
  • She joined Exscientia as Chief Information Officer in May 2022 from Wellcome Trust, where she formed part of the senior leadership and led digital transformation as Head of Technology.

Arqit: Accelerating 5G Open-RAN to meet the UK's future communications needs to develop new telecoms networks for the UK

Retrieved on: 
Wednesday, June 14, 2023
Data infrastructure, Heart, SDR, Open, CSA, Telecommunications, Internet of things, Medicines Discovery Catapult, MEC, DCMS, Innovation, Research, RAN, GSMA, Government, O/S, Radio access network, Radio, Commercial, GPP, Slipstream, MPN, Catapult, Renewable energy, Mobile phone

The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.

Key Points: 
  • The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.
  • The Secure 5G project will pave the way for more secure and competitive telecoms networks in the UK, benefiting industries across the board.
  • Secure 5G will accelerate the pace of innovation and further enable secure communications via a UK sovereign supply chain.
  • The technology developed by the consortium will accelerate Open-RAN through a powerful, secure and scalable 5G solution to meet the UK's future communications needs.

Arqit: Accelerating 5G Open-RAN to meet the UK's future communications needs to develop new telecoms networks for the UK

Retrieved on: 
Wednesday, June 14, 2023
Data infrastructure, Heart, SDR, Open, CSA, Telecommunications, Internet of things, Medicines Discovery Catapult, MEC, DCMS, Innovation, Research, RAN, GSMA, Government, O/S, Radio access network, Radio, Commercial, GPP, Slipstream, MPN, Catapult, Renewable energy, Mobile phone

The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.

Key Points: 
  • The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.
  • The Secure 5G project will pave the way for more secure and competitive telecoms networks in the UK, benefiting industries across the board.
  • Secure 5G will accelerate the pace of innovation and further enable secure communications via a UK sovereign supply chain.
  • The technology developed by the consortium will accelerate Open-RAN through a powerful, secure and scalable 5G solution to meet the UK's future communications needs.

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
Tuesday, April 25, 2023
Translation, Huntington's disease, HD, Medicines Discovery Catapult, Innovate UK, Therapy, HTT, Disease, Neurodegenerative disease, Hope, Head, Max, Antibody, Molecular medicine, Data analysis, Innovation, Drug discovery, Microglia, Entrepreneurship, Conference, Pharmaceutical industry, Vaccine, Huntingtin

CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.

Key Points: 
  • CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.
  • The data to be presented builds on a successful collaboration with Medicines Discovery Catapult and has been, in part, funded by two Innovate UK grants.
  • Young Kwon, Chief Executive Officer of Alchemab, said: "Huntington's Disease is a devastating neurodegenerative disorder and has proven to be very difficult to treat.
  • Presenter: Donna Finch, Head of Translational and Clinical Science, Alchemab Therapeutics
    Date and Time: Wednesday, April 26, Session III: Novel mechanisms, modalities, and candidates for HD therapeutics, 9:00am-12:20pm CEST

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
Tuesday, April 25, 2023
Translation, Huntington's disease, HD, Medicines Discovery Catapult, Innovate UK, Therapy, HTT, Disease, Neurodegenerative disease, Hope, Head, Max, Antibody, Molecular medicine, Data analysis, Innovation, Drug discovery, Microglia, Entrepreneurship, Conference, Pharmaceutical industry, Vaccine, Huntingtin

CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.

Key Points: 
  • CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.
  • The data to be presented builds on a successful collaboration with Medicines Discovery Catapult and has been, in part, funded by two Innovate UK grants.
  • Young Kwon, Chief Executive Officer of Alchemab, said: "Huntington's Disease is a devastating neurodegenerative disorder and has proven to be very difficult to treat.
  • Presenter: Donna Finch, Head of Translational and Clinical Science, Alchemab Therapeutics
    Date and Time: Wednesday, April 26, Session III: Novel mechanisms, modalities, and candidates for HD therapeutics, 9:00am-12:20pm CEST

Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations

Retrieved on: 
Wednesday, March 1, 2023
Medicines Discovery Catapult, DNA, University, University College London, Genomics, IVD, Pancreatic cancer, Engineering, Doctor of Philosophy, Physics, King's College London, Electronic, Lighthouse Labs, Electrical engineering, Imperial College London, COVID, Biochemical engineering, Management

The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.

Key Points: 
  • The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.
  • Karl was one of the original members and the first Operations Director of Oxford Gene Technology, a pioneer of DNA microarray technology.
  • During the pandemic Karl was Head of Operations at the Medicines Discovery Catapult, Lighthouse Lab - one of the UK´s network of COVID testing labs.
  • Karl's background in leading operations will further ensure streamlined performance across all departments," says Philipp Mathieu, CEO and President of Immunovia.

Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations

Retrieved on: 
Wednesday, March 1, 2023
Medicines Discovery Catapult, DNA, University, University College London, Genomics, IVD, Pancreatic cancer, Engineering, Doctor of Philosophy, Physics, King's College London, Electronic, Lighthouse Labs, Electrical engineering, Imperial College London, COVID, Biochemical engineering, Management

The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.

Key Points: 
  • The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.
  • Karl was one of the original members and the first Operations Director of Oxford Gene Technology, a pioneer of DNA microarray technology.
  • During the pandemic Karl was Head of Operations at the Medicines Discovery Catapult, Lighthouse Lab - one of the UK´s network of COVID testing labs.
  • Karl's background in leading operations will further ensure streamlined performance across all departments," says Philipp Mathieu, CEO and President of Immunovia.

SEEQC Partners With BASF To Explore Applications of Quantum Computing in Chemical Reactions for Industrial Use

Retrieved on: 
Thursday, February 9, 2023
Technology, Engineering, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, Software, General Health, Hardware, Science, Semiconductor, Data Management, Oxford Instruments, Chemical industry, SFQ, Merck Group, Medicines Discovery Catapult, NISQ, University, Science and Technology Facilities Council, Merck, Hartree Centre, Pharmacy, Partnership, BASF, Drug discovery, Microscope, Fine chemical

SEEQC, the digital quantum computing company, and BASF, the world’s largest chemical company, today announced a partnership to explore the application of quantum computing in chemical reactions.

Key Points: 
  • SEEQC, the digital quantum computing company, and BASF, the world’s largest chemical company, today announced a partnership to explore the application of quantum computing in chemical reactions.
  • SEEQC will use its proprietary digital chip-based quantum computer to scale support of commercial simulations in industrial catalysts.
  • “SEEQC is addressing the bottlenecks of scaling by integrating critical system functionality on a unique system-on-a-chip quantum computing platform,” said Horst Weiss, vice president, Next Generation Computing at BASF.
  • Through these partnerships, SEEQC will deliver platforms that support applications within the chemical and pharmaceutical industry, ensuring SEEQC and its partners have early access to two key markets for quantum computing.

Gilde Healthcare establishes world-leading Impact Council

Retrieved on: 
Tuesday, November 29, 2022
Newton, GDP, Medical Products Agency (Sweden), Pharmaceutical industry, European Medicines Agency, Mass, Patient, Private equity, Conditional sentence, NICE, Policy, Union, Medicines Discovery Catapult, Hospital, Health care, Massachusetts General Hospital Psychiatry Academy, Harvard Medical School, EMA, Medtech, Newton-Wellesley Hospital, Pharmacist, Executive Committee, ICER, Association of British HealthTech Industries, Association of the British Pharmaceutical Industry, Assistant, CADTH, Tufts Medical Center, General partnership, Division, Medical device, Management, Health insurance, Medicine, Humana

UTRECHT, Netherlands, Nov. 29, 2022 /PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with 2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council.

Key Points: 
  • UTRECHT, Netherlands, Nov. 29, 2022 /PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with 2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council.
  • Chaired by Professor Guido Rasi, former Executive Director of the European Medicines Agency (EMA), the Impact Council will play a pivotal role in assessing the impact on the healthcare system by Gilde Healthcare and its Venture&Growth portfolio companies.
  • Joep Muijrers, General Partner at Gilde Healthcare and responsible within Gilde Healthcare for coordinating the Impact Council, commented: "We are honoured to be working with such an established and experienced group of experts.
  • Pieter van der Meer, Managing Partner at Gilde Healthcare commented: "The Impact Council demonstrates our commitment to effectuate change in the healthcare sector.